Trial Profile
A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants With Advanced Hepatocellular Carcinoma (LEAP-002)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms LEAP-002
- Sponsors Merck Sharp & Dohme
- 20 Jan 2024 Results assessing safety and efficacy of Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma presented at the 2024 Gastrointestinal Cancers Symposium
- 16 Jan 2024 According to Eisai media release, data from this trial will be presented at ASCO GI 2024.
- 01 Dec 2023 Results of final analysis reporting efficacy and safety data published in the Lancet Oncology